TP53 and rhabdomyosarcoma: Furthermore, Meister et al. employed CRISPR/Cas9 to genetically edit rhabdomyosarcoma cells, demonstrating the increased sensitivity of p53-deficient rhabdomyosarcoma cells to the checkpoint kinase inhibitor prexasertib [33].